GLA and Fabry disease: [23] One-hundred-fifty milligrams administered every other day was evaluated in Phase 2 studies and is currently being evaluated in Phase 3 studies as a single agent for the treatment of Fabry disease in patients with GLA mutations that are amenable to chaperone therapy.